MeiraGTx (MGTX) said Monday that AAV2-hAQP1 received regenerative medicine advanced therapy designation from the US Food and Drug Administration.
AAV2-hAQP1 is being developed for the treatment of grade 2/3 radiation-induced xerostomia, a common side effect of head and neck cancer radiotherapy that causes dry mouth, according to the company.
The company's drug candidate also received orphan drug designation from the FDA previously and the RMAT designation will allow for frequent regulatory interactions with the agency, MeiraGTx said.
Shares of the company were up 6.1% in recent trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments